The Multiple Myeloma Research Consortium (MMRC) and Merck initiated a Phase IIb study of Zolinza (Merck’s vorinostat), an oral histone deacetylase (HDAC) inhibitor, in combination with Velcade (Millennium’s bortezomib) for Injection, a proteasome inhibitor, in patients with relapsed and refractory multiple myeloma.  The multicenter, open-label trial is sponsored by Merck and is part of the VANTAGE (Vorinostat Clinical Trials in Hematologic and Solid Malignancies) program. The tri...